Before DAA therapy, higher levels of liver enzymes (AST, ALT, and GGT), platelet count, and increased levels of hepatic fibrosis markers (assessed using the APRI and FIB-4 scores) were found in HIV/HCV-coinfected patients compared with the PLWH cohort of patients who had never had hepatitis C, suggesting greater liver damage in the HIV/HCV group. The gene discussed is GPT; the disease is Hepatic fibrosis.